Patents Examined by Agnes B. Rooke
  • Patent number: 7485622
    Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: February 3, 2009
    Assignee: BioProspecting NB Inc.
    Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
  • Patent number: 7473538
    Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: January 6, 2009
    Assignee: Ceres, Inc.
    Inventors: Nickolai Alexandrov, Vyacheslav Brover, Kenneth Feldmann
  • Patent number: 7462463
    Abstract: The present invention provides a microarray having one or more fusion proteins non-covalently attached to a solid support. Non-covalent attachment is achieved by designing a fusion protein having a polyanionic domain attached to a subject protein, and attaching the fusion protein to a solid support having a polycationic coating.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: December 9, 2008
    Assignee: California Institute of Technology
    Inventor: David A. Tirrell
  • Patent number: 7462460
    Abstract: The present invention provides methods for identifying evolutionarily significant polynucleotide and polypeptide sequences in human and/or non-human primates which may be associated with a physiological condition, such as enhanced resistance to HCV infection. The invention also provides methods for identifying evolutionarily significant polynucleotides with mutations that are correlated with susceptibility to diseases, such as BRCA1 exon 11. The methods employ comparison of human and non-human primate sequences using statistical methods. Sequences thus identified may be useful as host therapeutic targets and/or in screening assays.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: December 9, 2008
    Assignee: Evolutionary Genomics, Inc.
    Inventors: Walter Messier, James Sikela
  • Patent number: 7459169
    Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: December 2, 2008
    Assignee: Allvivo, Inc.
    Inventors: Bo Nilsson, Jonas Andersson, Karin Caldwell, Jennifer A. Neff, Kristina Nilsson-Ekdahl
  • Patent number: 7439337
    Abstract: The present invention is a kit and method for purifying a protein of interest.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: October 21, 2008
    Assignee: Rutgers, the State University of New Jersey
    Inventor: William W. Ward
  • Patent number: 7420038
    Abstract: FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are also disclosed.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: September 2, 2008
    Assignee: New York University
    Inventors: Tung-Tien Sun, Qiong Cao
  • Patent number: 7420033
    Abstract: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: September 2, 2008
    Assignee: Agennix, Inc.
    Inventors: Atul Varadhachary, Peter Glynn, Karel Petrak, Jose Engelmayer
  • Patent number: 7417120
    Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1? was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40-50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat1 known to be phosphorylated in vivo.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: August 26, 2008
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, James E. Darnell, Jr.
  • Patent number: 7414026
    Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-?B) activating pathway useful in the treatment of NF-?B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I?B.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: August 19, 2008
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
  • Patent number: 7399610
    Abstract: The present invention provides a simple cell-free protein synthesis method capable of affording synthesis of a protein in a high amount in a short time at a low cost. A method for cell-free protein synthesis using an extract derived from an insect cell, the method comprising removing a component which can pass through a semipermeable membrane through the semipermeable membrane while maintaining synthesis reaction, thereby to continuously synthesize a protein. Preferably, an mRNA is additionally supplied while said synthesis reaction is maintained. Further, said insect cell is preferably an established culture cell derived from Trichoplusia ni ovum cell.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: July 15, 2008
    Assignee: Shimadzu Corporation
    Inventors: Masamitsu Shikata, Nobuhiro Hanafusa, Shinichiro Kobayashi
  • Patent number: 7381538
    Abstract: A distal tip, and associated method of producing, of a biosensor ion sensing transducer for use in detecting an analyte comprising an halogenated organic compound in an environment such as soil or an aqueous environment. Features include: a biocomponent comprising at least one enzyme for carrying out a dehalogenation of the compound; the biocomponent is immobilized to a surface of the tip; a treatment of the biocomponent for maintaining a period of enzymatic efficacy; and the biocomponent stabilized by means preferably selected from the group consisting of crosslinking a surface of the immobilized biocomponent, crosslinking a polymer layer to the biocomponent, adding a gel-hardening agent to the biocomponent, adding a stabilizing agent to the biocomponent, and modifying a component of the immobilizing means. Immobilization can be carried out by: (a) entrapment within a hydrogel; (b) entrapment within a polymeric network; (c) (micro)encapsulation; (d) covalent-bonding; and (e) adsorption.
    Type: Grant
    Filed: June 1, 2002
    Date of Patent: June 3, 2008
    Assignee: Colorado State University Research Foundation (CSURF)
    Inventors: Kenneth F. Reardon, Neema Das
  • Patent number: 7378495
    Abstract: Compositions comprising PTH-rP peptides, combinations thereof, and multiepitope PTH-rP peptides, vectors for their delivery to antigen presenting cells, as well as methods are provided which are useful in the immunotherapy of parathyroid hormone related peptide expressing malignancies.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: May 27, 2008
    Assignee: Pevion Biotech, Ltd.
    Inventors: Pierpaolo Correale, Maria Grazia Cusi, Guido Francini
  • Patent number: 7371820
    Abstract: The invention relates to a method for isolating from connective tissue a variety of glycosaminoglycan (GAG)-polypeptide complexes and polypeptides which are substantially free of contaminating DNA and other molecules such as viruses which may be associated with the DNA in the cell. The invention also relates to uses of GAG-peptide complexes and polypeptides substantially free of DNA either directly, or after further processing, for the treatment, protection and restoration of connective tissues in inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis in any of their multiple forms or other degenerative conditions in mammals.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: May 13, 2008
    Assignee: Institute of Nutraceutical Research PTY Ltd.
    Inventors: Bojang Shen, Peter Ghosh
  • Patent number: 7358337
    Abstract: A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is ?-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: April 15, 2008
    Assignee: International Technidyne Corporation
    Inventors: Ted C. K. Lee, Amanda B. McBride, Frank M. LaDuca
  • Patent number: 7351800
    Abstract: This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: April 1, 2008
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Toshiya Kai, Makoto Sato
  • Patent number: 7341850
    Abstract: This invention provides novel human LXR? variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: March 11, 2008
    Assignee: Wyeth
    Inventors: Qiang-Yuan Liu, Ponnal Nambi
  • Patent number: 7335734
    Abstract: The invention of this application provides a protein polymer of 8 to 15 proteins in association, wherein each protein has the amino acid sequence of SEQ ID NO: 1, and where the protein polymer has an unfold activity on the higher-order structure of a protein and this protein polymer is useful for the development of therapeutic agents of various diseases due to the failure in the formation of the higher-order structure of a protein, and the like.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: February 26, 2008
    Assignee: Japan Science and Technology Corporation
    Inventors: Naomi Sakasegawa, Hiroyuki Sasaki, Shoichiro Tsukita
  • Patent number: 7329733
    Abstract: A novel Bacillus thuringiensis strain deposited at the International Depository Authority of Health Canada in Winnipeg under accession number IDAC010201-5, its crystal gene having the sequence SEQ ID NO: 1 and crystal protein encoded by same having the sequence SEQ ID NO: 2 and uses thereof. More specifically, the present invention is concerned with a novel Bacillus thuringiensis, novel cry31 protoxin and toxin, nucleotide sequences encoding same and anti-cancer therapeutic applications for the toxin.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: February 12, 2008
    Assignee: Agriculture Agroalimentaire Canada
    Inventors: Jean-Charles Côté, Yong-Chul Jung, Eiichi Mizuki, Tetsuyuki Akao
  • Patent number: 7309773
    Abstract: Flax protein isolates are obtained in a procedure in which flax oil seeds are initially extracted to remove mucilage therefrom prior to crushing to recover the oil and produce a meal. The flax protein meal then is processed to recover a flax protein isolate therefrom.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: December 18, 2007
    Assignee: Burcon Nutrascience (MB) Corp.
    Inventors: Brent E. Green, Radka Milanova, James Logie